These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25721922)

  • 1. Managing potential drug-drug interactions between gastric acid-reducing agents and antiretroviral therapy: experience from a large HIV-positive cohort.
    Lewis JM; Stott KE; Monnery D; Seden K; Beeching NJ; Chaponda M; Khoo S; Beadsworth MB
    Int J STD AIDS; 2016 Feb; 27(2):105-9. PubMed ID: 25721922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy.
    van Lunzen J; Liess H; Arastéh K; Walli R; Daut B; Schürmann D
    HIV Med; 2007 May; 8(4):220-5. PubMed ID: 17461849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug interactions between HIV protease inhibitors and acid-reducing agents.
    Falcon RW; Kakuda TN
    Clin Pharmacokinet; 2008; 47(2):75-89. PubMed ID: 18193914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy.
    Miller CD; El-Kholi R; Faragon JJ; Lodise TP
    Pharmacotherapy; 2007 Oct; 27(10):1379-86. PubMed ID: 17896893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of acid reduction with a proton pump inhibitor on the pharmacokinetics of lopinavir or ritonavir in HIV-infected patients on lopinavir/ritonavir-based therapy.
    Overton ET; Tschampa JM; Klebert M; Royal M; Rodriguez M; Spitz T; Kim G; Mondy KE; Acosta EP
    J Clin Pharmacol; 2010 Sep; 50(9):1050-5. PubMed ID: 20147613
    [No Abstract]   [Full Text] [Related]  

  • 6. Lack of effect of gastric acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir in HIV-infected patients.
    Chiu YL; Klein CE; Woodward WC; King KR; Naylor C; Awni W; Brun S
    AIDS Patient Care STDS; 2007 Apr; 21(4):247-51. PubMed ID: 17461719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions between protease inhibitors and acid-reducing agents: a systematic review.
    Béïque L; Giguère P; la Porte C; Angel J
    HIV Med; 2007 Sep; 8(6):335-45. PubMed ID: 17661841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of potential clinically significant drug interactions in HIV-infected patients: a comprehensive therapeutic approach.
    Iniesta-Navalón C; Franco-Miguel JJ; Gascón-Cánovas JJ; Rentero-Redondo L
    HIV Med; 2015 May; 16(5):273-9. PubMed ID: 25523089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acid suppressive therapy and the effects on protease inhibitors.
    Fulco PP; Vora UB; Bearman GM
    Ann Pharmacother; 2006 Nov; 40(11):1974-83. PubMed ID: 17077173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of possible drug-drug interactions between antiretroviral agents in different age groups in a section of the private health care sector setting in South Africa.
    Katende-Kyenda NL; Lubbe MS; Serfontein JH; Truter I
    J Clin Pharm Ther; 2008 Aug; 33(4):393-400. PubMed ID: 18613857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral therapy and resistance to antiretroviral drugs.
    Lange JM; van Leeuwen R
    Ethiop Med J; 2002 Apr; 40 Suppl 1():51-75. PubMed ID: 12802831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
    Joly V; Yeni P
    Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression.
    Cambiano V; Lampe FC; Rodger AJ; Smith CJ; Geretti AM; Lodwick RK; Holloway J; Johnson M; Phillips AN
    HIV Med; 2010 Mar; 11(3):216-24. PubMed ID: 20002781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Place of protease inhibitors in antiretroviral treatment.
    Tenore SB; Ferreira PR
    Braz J Infect Dis; 2009 Oct; 13(5):371-4. PubMed ID: 20428639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen.
    Burgos J; Crespo M; Falcó V; Curran A; Imaz A; Domingo P; Podzamczer D; Mateo MG; Van den Eynde E; Villar S; Ribera E
    J Antimicrob Chemother; 2012 Jun; 67(6):1453-8. PubMed ID: 22378681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of potential drug-drug interactions between antiretroviral drugs from prescriptions in the private health-care sector in South Africa.
    Katende-Kyenda NL; Lubbe MS; Serfontein JH; Truter I
    Int J STD AIDS; 2012 Mar; 23(3):166-72. PubMed ID: 22581868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
    Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F;
    Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.